Ignite Creation Date:
2024-10-25 @ 7:50 PM
Last Modification Date:
2024-10-26 @ 3:43 PM
Study NCT ID:
NCT06647927
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-10-16
Brief Title:
GenLab Unveiling the Genetic Landscape of Brugada Syndrome Novel Biomarker Discovery for Precise Diagnosis
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Unveiling the Genetic Landscape of Brugada Syndrome Novel Biomarker Discovery for Precise Diagnosis
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
GenLaB
Brief Summary:
This research makes several significant contributions to the field of BrS It employs advanced genetic sequencing techniques to develop a genetic signature to improve the accuracy and efficiency of BrS diagnosis The identification of specific biomolecular profiles and genetic signatures enhances our understanding of the syndromes molecular mechanisms facilitating targeted therapies and refined risk stratification These advancements optimize patient care by enabling personalized treatment plans and risk assessment Overall this research adds value by advancing diagnostic methods providing molecular insights optimizing patient care and positively impacting public health outcomes in BrS
Detailed Description:
Our work on BrS is dedicated to decipher the pathogenic mechanism and to ameliorate diagnostic approaches by developing a non-invasive test Employing a multi-omic strategy weve identified potential biomarkers across proteins metabolites and lipids leading to a filed patent for a promising biomolecular signature Additionally weve discovered associated gene mutations This grant proposal aims to enhance our preliminary findings by studying a larger BrS cohort supported by a meticulously curated patient registry By integrating advanced whole-exome sequencing WES and machine learning we aim to identify a genetic signature for BrS diagnosis and uncover altered pathways integral to BrS etiology This could refine risk stratification strategies contributing to improved diagnostic accuracy and deeper understanding BrS molecular mechanisms
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None